Abstract:Alexander disease (AxD) is a rare and fatal neurodegenerative disorder caused by mutations in the gene encoding glial fibrillary acidic protein (GFAP). In this report, a mouse model of AxD (GFAPTg;Gfap+/R236H) was analyzed that contains a heterozygous R236H point mutation in murine Gfap as well as a transgene with a GFAP promoter to overexpress human GFAP. Using label-free quantitative proteomic comparisons of brain tissue from GFAPTg;Gfap+/R236H versus wild-type mice confirmed upregulation of the glutathione metabolism pathway and indicated proteins were elevated in the peroxisome proliferator-activated receptor (PPAR) signaling pathway, which had not been reported previously in AxD. Relative protein-level differences were confirmed by a targeted proteomics assay, including proteins related to astrocytes and oligodendrocytes. Of particular interest was the decreased level of the oligodendrocyte protein, 2-hydroxyacylsphingosine 1-beta-galactosyltransferase (Ugt8), since Ugt8-deficient mice exhibit a phenotype similar to GFAPTg;Gfap+/R236H mice (e.g., tremors, ataxia, hind-limb paralysis). In addition, decreased levels of myelin-associated proteins were found in the GFAPTg;Gfap+/R236H mice, consistent with the role of Ugt8 in myelin synthesis. Fabp7 upregulation in GFAPTg;Gfap+/R236H mice was also selected for further investigation due to its uncharacterized association to AxD, critical function in astrocyte proliferation, and functional ability to inhibit the anti-inflammatory PPAR signaling pathway in models of amyotrophic lateral sclerosis (ALS). Within Gfap+ astrocytes, Fabp7 was markedly increased in the hippocampus, a brain region subjected to extensive pathology and chronic reactive gliosis in GFAPTg;Gfap+/R236H mice. Last, to determine whether the findings in GFAPTg;Gfap+/R236H mice are present in the human condition, AxD patient and control samples were analyzed by Western blot, which indicated that Type I AxD patients have a significant fourfold upregulation of FABP7. However, immunohistochemistry analysis showed that UGT8 accumulates in AxD patient subpial brain regions where abundant amounts of Rosenthal fibers are located, which was not observed in the GFAPTg;Gfap+/R236H mice.

Tissue and Cellular Rigidity and Mechanosensitive Signaling Activation in Alexander Disease

Adult-onset Alexander disease in people living with HIV and a novel mutation in GFAP

Glial fibrillary acidic protein is pathologically modified in Alexander disease

Aberrant neurodevelopment in human iPS cell-derived models of Alexander disease

Mutations in GFAP Disrupt the Distribution and Function of Organelles in Human Astrocytes

De novo mutations in GFAP cause Alexander disease: clinical features, fMRI and functional analysis

STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease

Metabolic Enzyme Alterations and Astrocyte Dysfunction in a Murine Model of Alexander Disease With Severe Reactive Gliosis

Relative stabilities of wild-type and mutant glial fibrillary acidic protein in patients with Alexander disease

Lysosomal function, resistance to stress and repair are compromised by expression of the Alexander disease GFAP R239C mutant

Establishment and Use of Primary Cultured Astrocytes from Alexander Disease Model Mice

Altered Extracellular Matrix Structure and Elevated Stiffness in a Brain Organoid Model for Disease

The Alexander Disease Protein GFAP Drives Mitochondrial Fission

Leukodystrophies with astrocytic dysfunction

A Report of Two Cases of Bulbospinal Form Alexander Disease and Preliminary Exploration of the Disease

A systematic review and meta-analysis of GFAP gene variants in Alexander disease

Mitochondria Are Dynamically Transferring Between Human Neural Cells and Alexander Disease-Associated GFAP Mutations Impair the Astrocytic Transfer

Clinical and genetic study in chinese patients with alexander disease

Membralin Deficiency Dysregulates Astrocytic Glutamate Homeostasis Leading to ALS-like Impairment.

Beneficial effects of curcumin on GFAP filament organization and down-regulation of GFAP expression in an in vitro model of Alexander disease

Intermediate filament dysregulation and astrocytopathy in the human disease model of KLHL16 mutation in giant axonal neuropathy (GAN)